DAKIKI Cells
USD$700.00*
Products are shipped frozen on dry ice in cryotubes. Each cryotube typically contains 3 × 106 cells for adherent lines or 5 × 106 cells for suspension lines (refer to the batch CoA for details).
General information
| Description | DAKIKI is a human Epstein-Barr virus (EBV)-positive B-lymphoblastoid cell line that expresses surface IgA1 and secretes polymeric IgA1. It was originally derived from peripheral lymphocytes of an adult patient with nasopharyngeal carcinoma and subsequently established as a continuously proliferating suspension culture. The cells exhibit typical lymphoblastoid morphology and grow in RPMI-based media supplemented with serum. DAKIKI has been widely used as a model of human IgA1-producing B cells, particularly for studies investigating immunoglobulin synthesis, regulation of secretion, and post-translational glycosylation. Biochemical and lectin-based analyses have demonstrated that IgA1 secreted by DAKIKI cells displays galactose-deficient O-linked glycans within the hinge region. Monosaccharide compositional analysis and lectin ELISA confirm enrichment of terminal or α2,6-sialylated N-acetylgalactosamine (GalNAc) residues, a glycoform characteristic of aberrantly glycosylated IgA1 observed in IgA nephropathy. Neuraminidase treatment markedly increases Helix aspersa agglutinin reactivity, indicating the presence of sialylated GalNAc structures. Functional assays using Golgi-enriched fractions from DAKIKI cells demonstrate CMP-NeuAc:GalNAc-IgA1 α2,6-sialyltransferase activity, confirming the capacity of these cells to directly sialylate Gal-deficient O-glycans. Transcriptional analyses reveal expression of ST6-GalNAcII but not ST6-GalNAcI, supporting the role of ST6-GalNAcII in mediating α2,6 sialylation of hinge-region GalNAc in IgA1. In addition to its utility in glycosylation research, DAKIKI has been evaluated for responsiveness to B-cell-inducing factors and phorbol esters, which can modulate immunoglobulin secretion in certain human B-cell lines. While DAKIKI constitutively secretes IgA, it has been included among EBV-transformed B-cell models used to study regulation of immunoglobulin production and differentiation states. Owing to its stable IgA1 secretion profile and reproducible production of galactose-deficient, α2,6-sialylated hinge-region glycans, DAKIKI represents a well-characterized in vitro system for investigating mechanisms of IgA1 glycosylation, B-cell differentiation, and the molecular pathogenesis of IgA-associated disorders. |
|---|---|
| Organism | Human |
| Tissue | Peripheral blood |
| Synonyms | DAKIKI, DAKIKI Clone 1 |
Characteristics
| Age | Unspecified |
|---|---|
| Gender | Unspecified |
| Ethnicity | African |
| Morphology | lymphoblast |
| Cell type | B-cell |
| Growth properties | Suspension |
Regulatory Data
| Citation | DAKIKI (Cytion catalog number 305928) |
|---|---|
| Biosafety level | 2 |
| NCBI_TaxID | 9606 |
| CellosaurusAccession | CVCL_3675 |
Biomolecular Data
Handling
| Culture Medium | RPMI 1640, w: 2.0 mM stable Glutamine, w: 2.0 g/L NaHCO3 (Cytion article number 820700a) |
|---|---|
| Supplements | Supplement the medium with 10% FBS |
| Dissociation Reagent | None |
| Subculturing | Gently homogenize the cell suspension in the flask by pipetting up and down, then take a representative sample to determine the cell density per ml. Dilute the suspension to achieve a cell concentration of 1 x 105 cells/ml with fresh culture medium, and aliquot the adjusted suspension into new flasks for further cultivation. |
| Seeding density | 2 to 5 x 105 cells/cm2 |
| Fluid renewal | 2 to 3 times per week |
| Freeze medium | As a cryopreservation medium, we use complete growth medium + 10% DMSO for adequate post-thaw viability. |
| Thawing and Culturing Cells |
|
| Incubation Atmosphere | 37°C, 5% CO2, humidified atmosphere. |
| Shipping Conditions | Cryopreserved cell lines are shipped on dry ice in validated, insulated packaging with sufficient refrigerant to maintain approximately −78 °C throughout transit. On receipt, inspect the container immediately and transfer vials without delay to appropriate storage. |
| Storage Conditions | For long-term preservation, place vials in vapor-phase liquid nitrogen at about −150 to −196 °C. Storage at −80 °C is acceptable only as a short interim step before transfer to liquid nitrogen. |
Quality Control & Molecular Analysis
Certificate of Analysis (CoA)
| Lot Number | Certificate Type | Date | Catalog Number |
|---|---|---|---|
| 305928-130426 | Certificate of Analysis | 15. May. 2026 | 305928 |